Historical Erlangen MTB protein-function interpretation
Prior P/LP, VUS and B/LB functional-impact review; different classification semantics from oncogenicity.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for Historical Erlangen MTB protein-function interpretation. Fields the record does not carry are marked not recorded.
Evaluations and results
1 evaluation · 2 results. Different protocols are not a single leaderboard.
Protocol: OncoVI three-class assessment: MTB selected expert reassessment · Dataset: MTB selected expert reassessment
Sorted by Percent agreement (vs expert reassessment) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Percent agreement (vs expert reassessment) | Count (expert-concordant variants) |
|---|---|---|
| Historical Erlangen MTB protein-function interpretationEvaluation | 34% | 46 |
All 2 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: Historical Erlangen MTB protein-function interpretation | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 34% Percent agreement (vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceHistorical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A |
| Configuration: Historical Erlangen MTB protein-function interpretation | Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment | 46 Count (expert-concordant variants) count · unknown Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceHistorical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A |
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Use this configuration
How it works, versions and access
Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
1 evidence row matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Facets: method types1 values
| Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology OncoVI Methods: "an IF-ELSE implementation" of the points-based SOP Version: 2026 final full text in Europe PMC XML | conflicting claim ["source-hash-verification","automated-source-review"] · 2026-10-12 Audit detailsCorrect the method type from none to conventional_pipeline (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md. Conflicting source claim: Field: Claim: metadata-correction-tags-20261012-728d501bd0cbc2676d64 Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Extraction artifact SHA-256: |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Original source · 2026 final full text in Europe PMC XML
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID uc-clinical-20260930-oncovi-prior-mtb.
Related records
How to cite
Historical Erlangen MTB protein-function interpretation. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/uc-clinical-20260930-oncovi-prior-mtb/
Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence